Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 38Lung Neoplasms 21Carcinoma, Hepatocellular 18Breast Neoplasms 16Small Cell Lung Carcinoma 14Urinary Bladder Neoplasms 9Squamous Cell Carcinoma of Head and Neck 7Liver Neoplasms 7Neoplasm Metastasis 6Triple Negative Breast Neoplasms 5Pancreatic Neoplasms 5Ovarian Neoplasms 5Neoplasms 5Endometrial Neoplasms 5Carcinoma, Transitional Cell 5Carcinoma, Renal Cell 5Carcinoma 5Biliary Tract Neoplasms 5Stomach Neoplasms 4Melanoma 4Colorectal Neoplasms 4Cholangiocarcinoma 4Prostatic Neoplasms 3Neoplasms by Site 3Esophageal Neoplasms 3Carcinoma, Squamous Cell 3Uterine Cervical Neoplasms 2Turcot syndrome 2Thyroid Neoplasms 2Thoracic Neoplasms 2

Interventions

Etoposide 3etoposide phosphate 2Paclitaxel 2Ifosfamide 2Cisplatin 2tremelimumab 1pembrolizumab 1durvalumab 1cabozantinib 1Sirolimus 1Quality of Life 1Proton Therapy 1Mesna 1Granulocyte Colony-Stimulating Factor 1Cyclophosphamide 1Celecoxib 1Carboplatin 1Bleomycin 1Automobiles 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Neoplasms, Germ Cell and Embryonal × durvalumab × Clear all
NCT03158064 2026-01-28

Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
30 enrolled

Nonseminomatous germ cell tumor, Dysgerminoma, Neoplasms, Germ Cell and Embryonal, Germinoma, Seminoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡